Komipharm International Co. Ltd (KQ:041960) — Market Cap & Net Worth
Market Cap & Net Worth: Komipharm International Co. Ltd (041960)
Komipharm International Co. Ltd (KQ:041960) has a market capitalization of $285.61 Million (₩421.45 Billion) as of August 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14946 globally and #469 in its home market, demonstrating a 3.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Komipharm International Co. Ltd's stock price ₩7290.00 by its total outstanding shares 57811900 (57.81 Million). See reinvestment intensity of Komipharm International Co. Ltd to understand how much of operating cash flow is reinvested back into capital assets.
Komipharm International Co. Ltd Market Cap History: 2015 to 2026
Komipharm International Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.19 Billion to $285.61 Million (-9.26% CAGR).
Index Memberships
Komipharm International Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$202.56 Billion | 0.14% | #141 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$202.56 Billion | 0.14% | #141 of 1384 |
Weight: Komipharm International Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Komipharm International Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Komipharm International Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Komipharm International Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.08 Billion | $37.64 Billion | $289.39 Million | 0.03x | 3.73x |
| 2017 | $1.18 Billion | $36.64 Billion | -$5.10 Billion | 0.03x | N/A |
| 2018 | $656.88 Million | $34.99 Billion | -$14.30 Billion | 0.02x | N/A |
| 2019 | $542.81 Million | $35.49 Billion | -$21.36 Billion | 0.02x | N/A |
| 2020 | $478.74 Million | $37.16 Billion | -$2.82 Billion | 0.01x | N/A |
| 2021 | $305.76 Million | $35.85 Billion | -$4.46 Billion | 0.01x | N/A |
| 2022 | $248.80 Million | $39.80 Billion | -$6.51 Billion | 0.01x | N/A |
| 2023 | $164.16 Million | $42.65 Billion | -$3.98 Billion | 0.00x | N/A |
| 2024 | $151.23 Million | $58.78 Billion | $13.11 Billion | 0.00x | 0.01x |
| 2025 | $275.03 Million | $52.47 Billion | -$7.21 Billion | 0.01x | N/A |
Competitor Companies of 041960 by Market Capitalization
Companies near Komipharm International Co. Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Komipharm International Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5813 globally with a market cap of $2.17 Billion USD ( ₩3.20 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8292 globally with a market cap of $1.12 Billion USD ( ₩1.65 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9792 globally with a market cap of $791.32 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #11348 globally with a market cap of $572.28 Million USD ( ₩844.46 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5813 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.17 Billion | ₩149600.00 |
| #8292 | ST Pharm Co.Ltd | KQ:237690 | $1.12 Billion | ₩88500.00 |
| #9792 | NatureCell Co.Ltd | KQ:007390 | $791.32 Million | ₩22000.00 |
| #11348 | Oscotec Inc | KQ:039200 | $572.28 Million | ₩30050.00 |
Komipharm International Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Komipharm International Co. Ltd's market cap moved from $1.19 Billion to $ 285.61 Million, with a yearly change of -9.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩285.61 Million | +3.85% |
| 2025 | ₩275.03 Million | +81.87% |
| 2024 | ₩151.23 Million | -7.88% |
| 2023 | ₩164.16 Million | -34.02% |
| 2022 | ₩248.80 Million | -18.63% |
| 2021 | ₩305.76 Million | -36.13% |
| 2020 | ₩478.74 Million | -11.80% |
| 2019 | ₩542.81 Million | -17.36% |
| 2018 | ₩656.88 Million | -44.27% |
| 2017 | ₩1.18 Billion | +9.29% |
| 2016 | ₩1.08 Billion | -9.56% |
| 2015 | ₩1.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Komipharm International Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $285.61 Million USD |
| MoneyControl | $285.61 Million USD |
| MarketWatch | $285.61 Million USD |
| marketcap.company | $285.61 Million USD |
| Reuters | $285.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more